Good MorningEquity markets rebounded on Friday to end the week down slightly from the end of 2024. The move may indicate market weakness, but that has yet to be seen. As it is, the market remains above critical support levels and aligned with uptrends that are expected to continue. Price action on the daily chart suggests the rally could resume next week, and there are reasons to think it will. Next week will bring another round of economic data likely to show solid labor markets and consumer health, and the following week will be the beginning of peak earnings season. With economic health and earnings growth in the picture, it is unlikely that the S&P 500 will fall far if it does at all.
Oil is reemerging as a risk. The price of WTI advanced more than 5% last week and is on track to hit the top of its trading range in early Q1. The move is driven by the expectation for Trump's policies and surprise stimulus in China. China increased wages for a large portion of its economy to invigorate consumption. The risk is that higher oil prices will reinvigorate inflation and keep the Fed from further lowering rates. Featured: New deadline for the CLARITY Act (Ad) 
|
Business Services | |
As the world pushes for newer, innovative tech, there are many ways to invest in the future. Recently, autonomous drone stocks have yielded handsome returns. Mysterious drone sightings in the Northeastern U.S. helped drive this. Two companies working closely in this space are Red Cat (NASDAQ: RCAT... Read the Full Story |
|
From Our Partners | | Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accounts - and without a plan, those required minimum distributions can carry a serious tax cost.
SmartAsset's model suggests working with a fiduciary financial advisor could potentially add 36% to 212% more dollar value to a portfolio over a lifetime. Their no-cost tool matches you with vetted advisors in your area who are legally bound to act in your interest. | | Find and compare fiduciary financial advisors serving your area today |
|
Energy | |
Multiple factors, including forecasts for an extremely cold winter and rising natural gas prices, are driving a surge in diesel prices. The Department of Energy/Energy Information Administration (DOE/EIA) reported a $0.027 increase in the average retail diesel price, reaching $3.503 a gallon to cl... Read the Full Story |
|
Markets | |
Experts predict that the impact of climate change on everything from housing to public health will increase over time. A study by the Energy Policy Institute of the University of Chicago estimates that for every one degree Fahrenheit increase in average temperature, costs to the U.S. economy will ... Read the Full Story |
|
From Our Partners | | Your Download Link (Expiring)
If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires.
That way, no matter what it costs in the future, you'll have a free copy on your computer. | | Simple Options Trading For Beginners (Download Link Expires)... |
|
Technology | |
After Google's parent, Alphabet (NASDAQ: GOOGL), announced a breakthrough in quantum computing with its Willow chip, stocks linked to quantum tech have soared. Rigetti Computing (NASDAQ: RGTI) has seen its value rise several times over in just a month. However, one company that has seen a less sub... Read the Full Story |
|
Technology | |
The artificial intelligence (AI) market is experiencing exponential growth, and at the heart of this revolution lies the critical need for a solid infrastructure. Nebius Group N.V. (NASDAQ: NBIS) is a rising star in the AI infrastructure space, and the company is making waves with its unique AI-... Read the Full Story |
|
From Our Partners | | Jeff Brown and Marc Chaikin - two investors who called Nvidia a decade ago - say Elon Musk's newly filed AI patent could trigger a wealth wave they're calling his biggest breakthrough yet.
They're tracking a market pattern with a 100% historical track record of major gains, and they believe it's about to collide with this invention. The last time it triggered, investors had a chance to turn $10,000 into $350,000 in roughly 12 months. | | See the details on Elon's AI patent and what comes next |
|
Retail/Wholesale | |
Amazon (NASDAQ: AMZN), Meta Platforms (NASDAQ: AMZN), and Intuitive Surgical (NASDAQ: ISRG) are the stocks most sold by insiders in 2024, but investors should buy them all. While not closely related, they all are ground-breaking technology that has had a long-lasting impact on daily life. The effe... Read the Full Story |
|
Auto/Tires/Trucks | |
Rivian Automotive Inc. (NASDAQ: RIVN) stock is up more than 15% the morning after the company announced fourth-quarter deliveries that came in well above analysts’ estimates.
Better still, the electric vehicle (EV) manufacturer announced that it is no longer experiencing a component shor... Read the Full Story |
|
Retail/Wholesale | |
Polarizing activist short-seller Hindenburg Research—known for its bombshell reports alleging corporate fraud and other malfeasance by companies including Nikola Corp. (NASDAQ: NKLA) and India's Adani Group—published on January 2, 2025, an article about its latest target: Carvana Co. (... Read the Full Story |
|
Auto/Tires/Trucks | | The stock market is a popularity contest in the short term but a weighing machine in the long term. At least, that’s what Warren Buffett and Benjamin Graham, the fathers of value investing, think today. Investors today can see this trend at play through the way that attention has flown from th... Read the Full Story |
|
Energy | |
Constellation Energy (NASDAQ: CEG) stock is up over 8% on January 2, 2025, following news of landmark contracts with the U.S. government. This price increase underscores the company's growing prominence in the clean energy sector and signals a potential turning point for nuclear energy's role in... Read the Full Story |
|
Monday's Early Bird Stock Of The Day Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts. | Should I Buy Vertex Pharmaceuticals Stock? VRTX Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Vertex Pharmaceuticals was last updated on Sunday, July 12, 2026 at 6:19 PM.
Vertex Pharmaceuticals Bull Case -
The current stock price is around $580, reflecting strong market interest and confidence in the company's growth potential.
-
Vertex Pharmaceuticals Incorporated has received multiple "buy" ratings from analysts, indicating positive sentiment and strong expectations for future performance.
-
The company has a robust return on equity of nearly 24%, suggesting effective management and profitability, which can lead to higher shareholder returns.
-
Recent acquisitions, such as that of Crinetics, enhance Vertex's portfolio with approved therapies and promising pipeline assets, potentially increasing revenue streams.
-
Vertex Pharmaceuticals Incorporated has demonstrated consistent revenue growth, with quarterly revenue up by over 8% compared to the previous year, indicating strong demand for its products.
Vertex Pharmaceuticals Bear Case -
Despite positive ratings, there is a risk of market volatility that could impact stock performance, especially in the biotechnology sector.
-
Recent downgrades from some analysts, such as Weiss Ratings, suggest that not all market participants are confident in the company's future prospects.
-
High institutional ownership at nearly 91% may limit price appreciation potential, as large investors can influence stock movements significantly.
-
Vertex Pharmaceuticals Incorporated operates in a highly competitive industry, which poses risks related to innovation and market share.
-
Potential regulatory challenges could impact the approval and commercialization of new therapies, affecting future revenue growth.
| | View Today's Stock Pick |
|
